CBER chief Peter Marks (Jim Lo Scalzo/Pool via AP Images)
May 19, 2023 11:28 AM EDTUpdated May 25, 08:08 AM
Cell/Gene Tx
FDA+

CBER chief Pe­ter Marks to con­sid­er 'al­ter­na­tives' to clin­i­cal holds as they 'put shud­ders down in­vestors' spines'

Zachary Brennan

Senior Editor

As mem­bers of the House ex­pressed con­cerns with the num­ber of clin­i­cal holds at Pe­ter Marks’ Cen­ter for Bi­o­log­ics Eval­u­a­tion and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times